Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

Bernstein has recently initiated Merck & Co Inc (MRK) stock to Mkt Perform rating, as announced on October 17, 2024, according to Finviz. Earlier, on March 11, 2024, Societe Generale had reduced the ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

In addition, recent price cuts for Januvia under Medicare and a one-time acquisition-related charge impacting operating margins have further pressured Merck's stock performance. Moreover ...

Compared to the aggregate P/E ratio of the 37.23 in the Pharmaceuticals industry, Merck & Co Inc. has a lower P/E ratio of 19 ...

Jim Cramer: This Financial Stock Is A Buy, Likes Broadcom Broadcom ... citing promising data for ivonescimab in NSCLC and setting a $32 price target amid strong trial results.

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the ...

Merck KGaA is a healthcare/pharma company that I have been covering and investing in for about 2 years at this point. Q2 2024 ...

Currently, Merck's stock is trading at a price-to-earnings (PE) multiple of 13.6, which is lower than many of its industry peers. In other recent news, Merck & Co. disclosed a 4% increase in third ...